Skip to main content

Table 4 Evolution of biomarkers during the study compared to pretreatment (basal) value

From: A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features

  Arm A Arm B
(BVZ + CAP + RT) (CAP + RT)
  VEGF VEGFR-2 Ang-2 MVD b VEGF VEGFR-2 Ang-2 MVD b
Basal         
 n 18 18 18 12 23 23 23 18
 Median 56 9056 2424 14 85 9282 3609 14
p NA NA NA NA NA NA NA NA
D15a         
 n 18 18 18 12 23 23 23 18
 Median 13 7 22 8 40 4 16 34
p 0.19 0.18 0.04 0.73 0.11 0.33 0.11 0.03
D57a         
 n 14 14 13 NA 17 17 17 NA
 Median 55 7 16 NA 13 2 20 NA
p 0.03 0.20 0.20 NA 0.71 0.86 0.01 NA
  1. Abbreviations: IQR interquartile range, VEGF vascular endothelial growth factor, VEGFR-2 circulating soluble VEGF receptor 2, Ang-2 angiopoietin-2.
  2. aPercent difference (%) = [(Later value- Basal value)/Basal value] × 100.
  3. bTissue samples (baseline and at surgery).